Visionary Leader, Problem Solver, Passionate Do'er.
Guiding Principle
Guiding Principle
Guiding Principle
If we do know the science around the target or drug, and have a deep understanding of the disease biology, along with expertise of dosing & pharmacology, we can achieve >90% success.
The problem is that most people don’t know what they don’t know, thus fail to see the forest for the trees.
Goals
Guiding Principle
Guiding Principle
Unique Approach to
1. Solve the Most Difficult Problem in the Development of Modern Medicine: 90% Failure.
2. Find the Right Drug for the Right Patient at the Right Time with the Right Dose!
Core Competences
Guiding Principle
Core Competences
Tactic: MoA-Disease Match Precision.
1. Retina & Glaucoma Specialty Care and Cornea & Ocular Surface Diseases.
2. Stem Cell & Gene Therapy, Drug and Combination Product Development.
A validated Approach to Transform Medicine Development.
Unique Clinical Data Expertise
Unique Clinical Data Expertise
Unique Clinical Data Expertise
Use Synthetic Thinking to Intercept Clinical Data: Seeing the Elephant.
R&D Clinical Pipeline Strategy
Unique Clinical Data Expertise
Unique Clinical Data Expertise
Conduct Strategic Review to Build Asset MoA-Disease Maps.
Intangible Assets
Unique Clinical Data Expertise
Intangible Assets
Proven Track Record of Success.
Intangible Assets and Know-How.
PHOTO GALLERY
1/5
Background and Examples of Success
Dr. Tina Guanting Qiu, MD, PhD (She/her): US citizen, a highly accomplished Biopharma physician executive with 25-year U.S. and international experience in global Pharma, biotech, device and strategic consulting firm. She has been championing for leveraging big data evidence to solve problems and create values for patients and shareholders in revolutionizing modern medicine development. She has held Leadership roles in scientific medical development, business and regulatory strategies, entrepreneurial startups, and external KOLs and shareholder relations.
Most recently Dr. Qiu serves as Consulting Chief Scientific & Medical Officer for Lineage Cell Therapeutics (LCT) on the world class human embryonic stem cell derived retinal pigment epithelium cell (hESC-RPE) transplantation for the treatment of age-related macular degeneration (AMD). She is the inventor for a novel approach to reprogram adult human retinal cells for retinal repair, along with colleagues at LCT, she contributed as co-inventor to the methods and use of hESC-RPE transplant for treating retinal diseases. She is the lead inventor for a novel angiogenesis model for wet AMD therapeutic development and pioneered in a minimally invasive subretinal delivery (SurModics RetinaJect, 2003) for gene & cell therapy and created a novel idea of using micro needle (Clearside Bio) for superachoroidal gene delivery to the retina (2015), collectively which has generated significant social economic impact in advancing these cutting edge therapies with clinical success, such as Luxturna, the first FDA approved human gene therapy for Leber congenital amaurosis (LCA2). Recently she established the first strategic clinical regulatory roadmap for hESC-derivative cell development, and a new regulatory standard of gene therapy for inherited retinal diseases.
As fellowship trained-retinal specialist working in industry, she also made measurable contributions in advancing glaucoma drug development and solving the most difficult problems, such as the discoveries of trabodenoson (adenosine A1 receptor agonist ) for its trabecular meshwork rejuvenation (Inotek Pharma), and Rescula (B-K channel activator) for its role in modulating parainflammation in glaucoma patient care (Sucampo). She also worked alongside with FDA and ASCRS top surgeons to help Alcon/Novartis solve the root cause of glaucoma Cypass withdrawal and advise on risk-mitigation strategy in 2019.
She has accrued many honors during her career, including the GSK Bronze Award for Outstanding Contributions for pioneering sustained release periOcular Drug Delivery Technology Innovation in 2007. She was also presented with a Translational Retinal Research Grant from National Eye Research Center in England in 2009, and a Best Paper Award from EC Ophthalmology in 2015. Her breakthrough research in retinal stem cell therapy was featuring at Scientific America in the USA, Bristol Evening Post and National Eye Research Center in England in 2009. Most recently she was being recognized by Marquis Who's Who for the Excellence in Ophthalmology and Marquis Humanitarian award in 2021.
She obtained her Medical Degree with Distinguished Honor at Nanchang University, and Doctorate of Ophthalmology at National Sun Yat-sen University in collaboration with University of Pennsylvania, followed by postdoctoral trainings at Boston University and Doheny Eye Institute at University Southern California. She was mentored by visionary and reknown retinal surgeon, Dr. Eugene de Juan Jr. and top industry executive leader, Mr. Paul G. Howes in the USA.
She is a lawful US Citizen since February, 2011.
Industry Background: Lineage Cell Therapeutics, Astellas Pharma, Sanofi Aventis, GlaxoSmothKline, Inotek Pharma, Sucampo Pharma, LambdaVision, Gerson Lehmarn Group.
1. 2023 European Ophthalmology Forum: https://www.dropbox.com/scl/fi/2fk02rkemu6cxn7qho3t4/Trabodenoson-OTI-OPH-European-Forum-Vienna-2023.mp4?rlkey=d0o0be49feaczly4dy4xnxvhs&dl=0
2. MDG-Boston Forum Nov. 9, 2022: Ocular Drug Delivery & Surgical Advances. https://www.mdgboston.org/event/ocular-drug-delivery-surgical-advances/
3. Marquis Who's Who 2021: https://www.24-7pressrelease.com/press-release/483959/dr-tina-guanting-qiu-recognized-by-marquis-whos-who-for-excellence-in-ophthalmology
4. Peer-review publications:
2019: MA09-hRPE transplant. npj Regenerative Medicine: https://www.nature.com/articles/s41536-019-0081-8
2021: Trabodenoson on Rejuvenation for Glaucoma: Expert Opin Investig Drugs: DOI: 10.1080/13543784.2021.1873276
Our Services
Retina Gene/Cell Therapy & Clinical Data Insight
IND and Phase 1-4 Clinical Protocol & Medical Strategy.
- Evidence-based Approach to Clinical Data Analysis;
- Biology-based Insight to Subreitnal Bleb Design & Procedure SOP.
R&D Strategic Review
Conduct Strategic Review to Build Asset MoA-Disease "Map" Franchise Indication & New Product Planning
Product Development Path-Finding to IND Enabling Stage
(up to 80% saving)
IND Package Review & "Must-Have"
Commercial Medical Affairs
KOLs Development & SAB Relations
Strategic Scientific Communication
Product Launch Taskforce
Product Medical Strategy
Medical Education & Trainings
Contact Us
Please send us a message for an appointment.
Ophthalmic Therapeutic Innovation MA
Qiu-Tina@Ophthalmic-Innovation.com Mobile: 001- 857 400 4607
Hours
Monday - Saturday: 8:00am - 5:00pm
Sunday: Closed
Our Partners
Copyright © 2023 Ophthalmic Therapeutic Innovation MA - All Rights Reserved.
Powered by GoDaddy Website Builder